Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) Shares Outstanding (Weighted Average): 2014-2025

Historic Shares Outstanding (Weighted Average) for Zevra Therapeutics (ZVRA) over the last 10 years, with Sep 2025 value amounting to $56.1 million.

  • Zevra Therapeutics' Shares Outstanding (Weighted Average) rose 6.68% to $56.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.1 million, marking a year-over-year increase of 6.68%. This contributed to the annual value of $53.4 million for FY2024, which is 47.37% up from last year.
  • Latest data reveals that Zevra Therapeutics reported Shares Outstanding (Weighted Average) of $56.1 million as of Q3 2025, which was up 2.66% from $54.7 million recorded in Q2 2025.
  • In the past 5 years, Zevra Therapeutics' Shares Outstanding (Weighted Average) ranged from a high of $56.1 million in Q3 2025 and a low of $28.4 million during Q1 2021.
  • Moreover, its 3-year median value for Shares Outstanding (Weighted Average) was $41.9 million (2024), whereas its average is $44.3 million.
  • As far as peak fluctuations go, Zevra Therapeutics' Shares Outstanding (Weighted Average) skyrocketed by 795.77% in 2021, and later declined by 2.31% in 2022.
  • Over the past 5 years, Zevra Therapeutics' Shares Outstanding (Weighted Average) (Quarterly) stood at $35.3 million in 2021, then decreased by 2.31% to $34.5 million in 2022, then rose by 4.97% to $36.2 million in 2023, then soared by 47.37% to $53.4 million in 2024, then increased by 6.68% to $56.1 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $56.1 million for Q3 2025, versus $54.7 million for Q2 2025 and $54.1 million for Q1 2025.